Century Therapeutics, Inc. (IPSC) Research
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Market snapshot
- Symbol
- IPSC
- Price
- $2.29
- Day change
- +1.78%
- Market cap
- $198.2M
- P/E ratio
- -1.84x
- 52-week range
- 0.435-3.04
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $3.00
Peer companies
Recent insider activity
- Russotti Gregory — S-Sale (2584 shares) on 2026-06-12
- Carr Douglas — S-Sale (1654 shares) on 2026-06-12
- Pfeiffenberger Brent — F-InKind (13849 shares) on 2026-06-11
- Cowan Chad — F-InKind (358 shares) on 2026-06-11
- Riva Alessandro — A-Award (74000 shares) on 2026-06-11
Open Century Therapeutics, Inc. (IPSC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.